Citadel Advisors’s Valion Bio VBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-2,966
Closed -$38.5K – 15237
2026
Q2
$38.5K Buy
+2,966
New +$64.5K ﹤0.01% 13237
2024
Q3
– Sell
-34
Closed -$5.63K – 15248
2024
Q2
$5.63K Buy
+34
New +$10.7K ﹤0.01% 13384
2023
Q4
– Sell
-39
Closed -$28.9K – 15261
2023
Q3
$28.9K Buy
+39
New +$72.1K ﹤0.01% 12302

Other funds holding VBIO

Citadel Advisors's VBIO Position: Q3 2026 in Review

Citadel Advisors sold out of Valion Bio (VBIO) in Q3 2026, closing a stake of 2,966 shares — an estimated $38.5K sold.

Citadel Advisors first reported a position in VBIO in Q3 2023 and held it in 3 quarters. The position peaked at $38.5K in Q2 2026. 8 funds tracked by Wall St. Rank hold VBIO as of Q3 2026.

  • Citadel Advisors reported no remaining Valion Bio position as of Q3 2026 after selling out during the quarter.
  • Citadel Advisors sold 2,966 Valion Bio shares in Q3 2026, an estimated $38.5K.
  • Citadel Advisors first reported a position in Valion Bio in Q3 2023 and held it in 3 quarters.
  • Citadel Advisors's Valion Bio position peaked at $38.5K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Valion Bio as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.